Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells

Most advanced prostate cancers progress to castration resistant prostate cancer (CRPC) after a few years of androgen deprivation therapy and the prognosis of patients with CRPC is poor. Although docetaxel and cabazitaxel can prolong the survival of patients with CRPC, inevitable progression appears...

Full description

Saved in:
Bibliographic Details
Main Authors: Bin Han, Naohiro Fujimoto, Mizuki Kobayashi, Tetsuro Matsumoto
Format: Article
Language:English
Published: Wiley 2012-01-01
Series:Prostate Cancer
Online Access:http://dx.doi.org/10.1155/2012/989214
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832558988986679296
author Bin Han
Naohiro Fujimoto
Mizuki Kobayashi
Tetsuro Matsumoto
author_facet Bin Han
Naohiro Fujimoto
Mizuki Kobayashi
Tetsuro Matsumoto
author_sort Bin Han
collection DOAJ
description Most advanced prostate cancers progress to castration resistant prostate cancer (CRPC) after a few years of androgen deprivation therapy and the prognosis of patients with CRPC is poor. Although docetaxel and cabazitaxel can prolong the survival of patients with CRPC, inevitable progression appears following those treatments. It is urgently required to identify better or alternative therapeutic strategies. The purpose of this study was to confirm the anti-cancer activity of zoledronic acid (Zol) and determine whether inhibition of geranylgeranylation in the mevalonate pathway could be a molecular target of prostate cancer treatment. We examined the growth inhibitory effect of Zol in prostate cancer cells (LNCaP, PC3, DU145) and investigated a role of geranylgeranylation in the anticancer activity of Zol. We, then, evaluated the growth inhibitory effect of geranylgeranyltransferase inhibitor (GGTI), and analyzed the synergy of GGTI and docetaxel by combination index and isobolographic analysis. Zol inhibited the growth of all prostate cancer cell lines tested in a dose-dependent manner through inhibition of geranylgeranylation. GGTI also inhibited the prostate cancer cell growth and the growth inhibitory effect was augmented by a combination with docetaxel. Synergism between GGTI and docetaxel was observed across a broad range of concentrations. In conclusion, our results demonstrated that GGTI can inhibit the growth of prostate cancer cells and has synergistic effect with docetaxel, suggesting its potential role in prostate cancer treatment.
format Article
id doaj-art-378547707018477f8b3e2188dec7d2d4
institution Kabale University
issn 2090-3111
2090-312X
language English
publishDate 2012-01-01
publisher Wiley
record_format Article
series Prostate Cancer
spelling doaj-art-378547707018477f8b3e2188dec7d2d42025-02-03T01:31:01ZengWileyProstate Cancer2090-31112090-312X2012-01-01201210.1155/2012/989214989214Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer CellsBin Han0Naohiro Fujimoto1Mizuki Kobayashi2Tetsuro Matsumoto3Department of Urology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi, Kitakyushu 807-8555, JapanDepartment of Urology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi, Kitakyushu 807-8555, JapanDepartment of Urology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi, Kitakyushu 807-8555, JapanDepartment of Urology, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi, Kitakyushu 807-8555, JapanMost advanced prostate cancers progress to castration resistant prostate cancer (CRPC) after a few years of androgen deprivation therapy and the prognosis of patients with CRPC is poor. Although docetaxel and cabazitaxel can prolong the survival of patients with CRPC, inevitable progression appears following those treatments. It is urgently required to identify better or alternative therapeutic strategies. The purpose of this study was to confirm the anti-cancer activity of zoledronic acid (Zol) and determine whether inhibition of geranylgeranylation in the mevalonate pathway could be a molecular target of prostate cancer treatment. We examined the growth inhibitory effect of Zol in prostate cancer cells (LNCaP, PC3, DU145) and investigated a role of geranylgeranylation in the anticancer activity of Zol. We, then, evaluated the growth inhibitory effect of geranylgeranyltransferase inhibitor (GGTI), and analyzed the synergy of GGTI and docetaxel by combination index and isobolographic analysis. Zol inhibited the growth of all prostate cancer cell lines tested in a dose-dependent manner through inhibition of geranylgeranylation. GGTI also inhibited the prostate cancer cell growth and the growth inhibitory effect was augmented by a combination with docetaxel. Synergism between GGTI and docetaxel was observed across a broad range of concentrations. In conclusion, our results demonstrated that GGTI can inhibit the growth of prostate cancer cells and has synergistic effect with docetaxel, suggesting its potential role in prostate cancer treatment.http://dx.doi.org/10.1155/2012/989214
spellingShingle Bin Han
Naohiro Fujimoto
Mizuki Kobayashi
Tetsuro Matsumoto
Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells
Prostate Cancer
title Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells
title_full Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells
title_fullStr Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells
title_full_unstemmed Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells
title_short Synergistic Effect of Geranylgeranyltransferase Inhibitor, GGTI, and Docetaxel on the Growth of Prostate Cancer Cells
title_sort synergistic effect of geranylgeranyltransferase inhibitor ggti and docetaxel on the growth of prostate cancer cells
url http://dx.doi.org/10.1155/2012/989214
work_keys_str_mv AT binhan synergisticeffectofgeranylgeranyltransferaseinhibitorggtianddocetaxelonthegrowthofprostatecancercells
AT naohirofujimoto synergisticeffectofgeranylgeranyltransferaseinhibitorggtianddocetaxelonthegrowthofprostatecancercells
AT mizukikobayashi synergisticeffectofgeranylgeranyltransferaseinhibitorggtianddocetaxelonthegrowthofprostatecancercells
AT tetsuromatsumoto synergisticeffectofgeranylgeranyltransferaseinhibitorggtianddocetaxelonthegrowthofprostatecancercells